Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Antiandrogens  COVID-19 treatment studies for Antiandrogens  C19 studies: Antiandrogens  Antiandrogens   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Death/ICU -23% Improvement Relative Risk c19early.org/aa Lazzeri et al. Antiandrogens for COVID-19 Prophylaxis Is prophylaxis with antiandrogens beneficial for COVID-19? Retrospective study in Italy Higher death/ICU with antiandrogens (not stat. sig., p=0.33) Lazzeri et al., medRxiv, doi:10.1101/2020.04.20.20068056 Favors various Favors control
Impact of anti-androgen therapies on COVID-19 susceptibility: a case-control study in male population from two COVID-19 regional centers of Lombardy (Italy)
Lazzeri et al., medRxiv, doi:10.1101/2020.04.20.20068056 (Preprint)
Lazzeri et al., Impact of anti-androgen therapies on COVID-19 susceptibility: a case-control study in male population from two.., medRxiv, doi:10.1101/2020.04.20.20068056 (Preprint)
Sep 2020   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective case-control study in Italy with 943 male COVID-19 patients, 45 on chronic 5ARI treatment (finasteride/dutasteride). There was significantly fewer COVID-19 patients >55 on 5ARI treatment compared to age-matched controls (5.57 vs. 8.14%, p=0.0083). The difference was greater for men aged >65 (7.14 vs. 12.31%, p=0.0001). There was no significant difference for ICU admission or death.
risk of death/ICU, 23.0% higher, OR 1.23, p = 0.33, multivariable, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Lazzeri et al., 21 Sep 2020, retrospective, Italy, preprint, 11 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperAntiandrogensAll
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2020.04.20.20068056; this version posted September 21, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Impact of anti-androgen therapies on COVID-19 susceptibility: a case-control study in male population from two COVID-19 regional centers of Lombardy (Italy) Massimo Lazzeri, MD-PhD1*, Stefano Duga, PhD1,2*, Elena Azzolini, MD1, Vittorio Fasulo, MD1, Nicolò Buffi, MD1-2, Alberto Saita, MD1, The Humanitas COVID-19 Task Force1, The Humanitas Gavazzeni COVID-19 Task Force3, Rodolfo Hurle, MD1, Alessandro Nobili, MD4, Maurizio Cecconi, MD-PhD1,2, Paolo Casale, MD1, Rosanna Asselta, PhD1,2 1 Humanitas Clinical and Research Center – IRCCS –, via Manzoni 56, 20089 Rozzano (Mi) – Italy 2 Humanitas University, Department of Biomedical Sciences, Via Rita Levi Montalcini 4, 20090 Pieve Emanuele – Milan, Italy 3 Humanitas Gavazzeni-Castelli, Bergamo, Italy 4 Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri, 2 , 20156, Milan *Equally contributed Short title: 5ARIs and the risk of COVID-19 Keywords: COVID-19, 5-alpha reductase inhibitors, androgens, sex. Manuscript word count: 1200 Corresponding Authors: Massimo Lazzeri, MD, PhD Department of Urology Istituto Clinico Humanitas IRCCS Via Manzoni 56 (20089) Rozzano – Milan (Italy) Email: massimo.lazzeri@humanitas.it Stefano Duga, PhD Department of Biological Sciences Humanitas University Via Rita Levi Montalcini 4 (20090) Pieve Emanuele - Milan (Italy) Email: stefano.duga@hunimed.eu NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2020.04.20.20068056; this version posted September 21, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . KEY POINTS Question: May treatment of benign prostatic hyperplasia with 5-alpha reductase inhibitors (5ARIs) impact on COVID-19-related hospitalization risk? Findings: In this case-control study, which compared 943 adult males hospitalized for COVID-19 with age-matched men from Lombardy (all beneficiaries of the Regional Health Service), the proportion of patients aged >55 years, who were exposed to 5ARIs (dutasteride, finasteride), was significantly lower (5.57%) than that of the general male population (8.14%) (p=0.0083, 95%CI=0.75-3.97%). Meaning: The use of 5ARIs was associated with a potential reduced risk of hospitalization for COVID-19 in men older than >55 years. This suggests the opportunity to test whether antiandrogen therapies can prevent the transition from paucisymptomatic SARS-CoV-2 infection to overt pulmonary disease. medRxiv preprint doi: https://doi.org/10.1101/2020.04.20.20068056; this version posted September 21, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . ABSTRACT Importance: There are gender differences in vulnerability to the Coronavirus..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit